Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.40 |
| ▸ | NPY1R | P25929 | 9/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.40 |
| ▸ | NPY2R | P49146 | 5/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30855541 | 1.00 | NPY4R (0.40) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL6038377 | 1.00 | NPY4R (0.40) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL30730451 | 0.96 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL30111320 | 0.94 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL27637834 | 0.94 | FOLH1 (0.44) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL27637835 | 0.94 | FOLH1 (0.44) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL15011349 | 0.92 | NPY4R (0.40) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL27732271 | 0.92 | NPY4R (0.40) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL9614927 | 0.92 | NPY4R (0.40) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL30563214 | 0.92 | NOD1 (0.40) | NPY4RNPY1RNPY5RNPY2RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060275213-A1 | Tumor targeting agents and uses thereof | KARYON OY (FI) | 2006-12-07 | — | — | US | disclosed |
| EP-1549669-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | Karyon OY (FI) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031221-A9 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004031221-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060275213-A1 | Tumor targeting agents and uses thereof | CCL2, CCL5, SCTR | NPY4R 1286/4885NPY1R 1427/4885NPY5R 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.